ArticleAnnals of thoracic surgery short reports2026
Sublobar Resection in Stage I Non-Small Cell Lung Cancer With Lymphovascular Invasion.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stage I lung cancer ≤2 cm is routinely being managed with sublobar (wedge or segmentectomy) resection. However, whether patients with lymphovascular invasion (LVI), an indicator of aggressive disease, gain similar benefits, is debated. Methods: A retrospective cohort analysis was conducted of 245 adult patients who underwent a resection for stage I non-small cell lung cancer (NSCLC) ≤2 cm at an academic institution from 2016 to 2022. Baseline characteristics were compared between patients with and without LVI. Overall survival and cumulative recurrence were compared using the Kaplan-Meier method. Results: LVI was present in 44 of 245 patients (18%) who underwent a resection for stage I lung cancer ≤2 cm. There was no difference in LVI based on comorbidities or pulmonary function. Patients with LVI were more likely to have poorly differentiated grade (59% vs 21%, Conclusions: For stage I NSCLC ≤2 cm with LVI-positive disease, there is no statistically significant difference in overall survival or cumulative recurrence between sublobar and lobar resections. Thus, a completion lobectomy likely offers no meaningful clinical benefit in this patient population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.